VEGF对缺血/再灌注损伤胰腺细胞凋亡的影响

目的 研究血管内皮生长因子(VEGF)对缺血/再灌注损伤胰腺组织细胞凋亡的影响.方法 将雄性sD大鼠30只随机分为3组(n=10),A组为假手术组,B组为缺血/再灌注损伤组,C组为缺血/再灌注损伤+VEGF反义寡核苷酸组.通过血管夹阻断大鼠腹腔干及肠系膜上动脉30 min,然后去除血管夹再灌注6 h,建立大鼠胰腺缺血/再灌注损伤模型.对各组胰腺组织进行VEGF免疫组化染色及TUNEL法细胞凋亡检测.结果 缺血/再灌注损伤后胰腺组织出现细胞凋亡,同时VEGF蛋白表达上调.缺血/再灌注损伤+VEGF反义寡核苷酸组的胰腺组织VEGF蛋白表达较缺血/再灌注损伤组显著减少(P<0.05),前者细胞凋亡指数较后者明显升高(P<0.05).结论 VEGF能抑制缺血/再灌注损伤胰腺细胞凋亡,可能对胰腺缺血再灌注损伤具有保护作用.     

Towards an understanding of salient neighborhood boundaries: adolescent reports of an easy walking distance and convenient driving distance

Numerous studies have examined the association between the surrounding neighborhood environment and physical activity levels in adolescents. Many of these studies use a road network buffer or Euclidean distance buffer around an adolescent's home to represent the appropriate geographic area for study (i.e., neighborhood). However, little empirical research has examined the appropriate buffer size to use when defining this area and there is little consistency across published research as to the buffer size used. In this study, 909 12^th grade adolescent girls of diverse racial and geographic backgrounds were asked to report their perceptions of an easy walking distance and a convenient driving distance. These two criterions are often used as the basis for defining one's neighborhood.     

DSA及动脉栓塞在骨与软组织肿瘤中的临床应用

目的:研究介入治疗在骨科肿瘤术前的临床应用价值。方法:对9例骨科肿瘤做介入治疗患者均行DSA造影,并用明胶海绵条做供养动脉栓塞。结果:肿瘤均有不同程度的坏死、液化和囊变,术中易剥离,出血少,术野清楚,缩短手术时间。结论:骨科肿瘤术前栓塞能够有效地减少术中失血,提高手术治疗成功率,是一种有价值的术前辅助性治疗方法。     

飞行人员脾脏海绵状血管瘤一例（摘要）

作者报道了飞行员的脾脏海绵状血管瘤一例,脾脏海绵状血管瘤在临床较为少见,其行成基础主要是脾血管瘤组织胎生发育异常,脾血管瘤一般多无临床症状,该病的诊断主要是通过结合超声等影像学检查手段。     

鼻内镜下鼻中隔穿孔修补15例临床分析

目的探讨经鼻内镜修补鼻中隔穿孔的手术方法及疗效。方法鼻中隔穿孔直径小于1.0 cm者鼻内镜下颞肌筋膜植入直接封闭,直径大于1.0 cm者鼻内镜下鼻底黏膜翻瓣或转移加筛骨垂直板和颞肌筋膜"三明治"式封闭,术后使用己烯雌酚纱布片贴附促进黏膜生长。结果直接封闭5例,翻瓣封闭6例,转移封闭4例,随访3~12个月,15例鼻中隔穿孔修补成功14例,成功率93.3%。结论鼻内镜下鼻中隔穿孔修补视野清晰,操作精细,大穿孔选用鼻底黏膜翻瓣或转移加筛骨垂直板和颞肌筋膜"三明治"式封闭成功率高。     

A southern analysis of Rh blood group genes: association between restriction fragment length polymorphism patterns and Rh serotypes

Polymorphisms within the Rh blood group system have been defined by serologic agglutination methods, but have not yet been defined at the DNA level. Two closely related genes associated with the Rh D antigen and with the Rh C/c and E/e antigens have been cloned. We used a Southern analysis incorporating probes to the 5' and 3' regions of the Rh C, E gene and D gene to identify polymorphisms associated with Rh C/c and E/e antigens, respectively. The D gene dosage could be determined by comparing the relative intensities of the D bands with bands from the 5' and 3' region of the Rh C, E gene. The concordance between restriction fragment length polymorphism (RFLP) patterns and serologic phenotypes for 102 randomly selected blood donors was 100% for C, e, and D, 94.8% for c, and 94.3% for E. The data are consistent with the sequences encoding the C/c epitopes residing on the 5' side of those for the E/e epitopes. All samples discordant for the 3' probe and E had the cE (r") serotype. These data show that the gene coding for the cE serotype is different in Rh-positive and -negative individuals. The study demonstrates that Rh DNA typing, including D gene dosage measurements and Rh gene haplotyping, may supplement traditional serotyping methods in transfusion medicine.     

A new Screening Tool for Detecting Early Atheroslerosis

In a study published in the current issue of the Journal of Geriatric Cardiology, Ang and co-investigators used the highresolution 64-slice CT coronary angiography to detect coronary lesions in a group of patients with atypical angina.1 The clinical data of these patients were also used to calculate their risk according the Framingham and PROCAM scoring system.2,3 As the cohort is composed with a majority of low risk patients with atypical angina, only a small minority of the patients were classified as having medium and high risk. The results showed that MDCT uncovered 18% either significant lesions (＞50% stenosis) or calcifications (＞400Agatston units)in the low risk patients and 33% in the medium and high risk subgroups.……